The iso-oncotopic response: immunotherapy-associated bullous pemphigoid in tumour footprints

Clin Exp Dermatol. 2022 Jul;47(7):1379-1381. doi: 10.1111/ced.15177. Epub 2022 May 14.

Abstract

This case report describes a unique distribution of bullous pemphigoid induced by cemiplimab therapy. The patient preferentially developed bullae in the scar "footprints" of previous non-melanoma skin cancers, yet traumatic scars were spared. We propose to describe this distribution as an 'iso-oncotopic response'.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Humans
  • Immunologic Factors
  • Immunotherapy / adverse effects
  • Neoplasms*
  • Pemphigoid, Bullous* / chemically induced
  • Pemphigoid, Bullous* / drug therapy

Substances

  • Immunologic Factors